HomeEXECUTIVES
EXECUTIVES
The medical device news magazine is the latest source for industry scoop. In this article, we take a look at which executives are on the move.
As the medical device industry rapidly expands, so does the need for executive leadership. Recently, several top executives have made moves within the industry. Some have taken new positions at other companies, while others have started their own businesses. Here’s a look at who’s been making headlines lately.
Chris McHugh Joins Zeus as Senior Vice President of Integrated Supply Chain
Chris McHugh has been named Senior Vice President of Integrated Supply Chain at Zeus and will be responsible for end-to-end operations across the company’s global network of manufacturing facilities
LeAnn Boyd Joins Presenters at Women Leaders in Healthcare Conference
Selected by Modern Healthcare as one of its Women Leaders for 2024, LeAnn Boyd is among an elite group of influential women working to improve the patient experience while advancing the objectives of their own organizations.
Josh Smale Appointed VP of Global Clinical and Scientific Affairs at R3 Vascular
Commenting on the appointment of Mr. Josh Smale, Christopher M. Ownes, President and CEO of R3 Vascular said, “On behalf of the R3 management team, I am very pleased to welcome Josh Smale as Vice President of Global Clinical and Scientific Affairs. Josh has a proven track record and more than 20 years of relevant medical device experience specializing in clinical and regulatory affairs strategy, clinical evidence generation and dissemination, and physician education. Among other key clinical and scientific affairs programs, Josh will lead our clinical trial efforts, including our pivotal ELITE trial for our next generation Magnitude drug eluting bioresorbable scaffold. We look forward to his contributions as we work towards establishing R3 Vascular as the leader in the development and manufacturing of fully bioresorbable vascular scaffolds.”
Long-time Collaborators Botond Roska and José-Alain Sahel Win the Wolf Prize 2024 in the Field of Medicine
The Wolf Prize, considered one of the most prestigious international awards, recognizes outstanding achievements in various fields including medicine.
LIfT BioSciences Appoints Antonin (Tony) de Fougerolles as Chairman of its Board of Directors
Alex Blyth, Chief Executive Officer of LIfT BioSciences commented: “On behalf of LIfT’s Board of Directors, I am pleased to welcome Tony to the Company as Chairman. Tony has extremely relevant experience, having played a key role in successfully bringing three new drug modalities to the market, extensive experience in immuno-oncology, and has helped build several multi-billion-dollar companies from start-up stage. This wealth of experience will prove invaluable to LIfT as we prepare to move into clinical trials for our allogeneic first-in-class neutrophil-based immuno-cell therapy and other exciting pipeline developments.”
Ronil Patel Appointed Chief Business Officer at RevOpsis Therapeutics
Ronil Patel currently serves as a strategic advisor to Collage Venture Partners and was previously the Chief Business Officer at Ocuphire Pharma, a publicly traded ophthalmology biotechnology company. Prior to Ocuphire, Patel led business development for Point Guard Partners and Oculos Clinical Research (now iuvo Bioscience). Patel has been instrumental in biotech research and development and global business expansion. He has also contributed to teams that have secured approximately $100 million in funding and finalized licensing and exit deals valued at over $500 million.
Julie Sawyer Montgomery | Appointed Executive Vice President for Diagnostics at Danaher Corporation
Julie Sawyer Montgomery currently Vice President and Group Executive of Danaher's Clinical Diagnostics businesses, will become an executive officer of Danaher reporting to the President and Chief Executive Officer, Rainer Blair.
Mark Eisner MD, M.P.H. Appointed Chief Medical Officer at Vir Biotechnology
Mark Eisner MD comes from Sonoma Biotherapeutics, Inc., where he most recently held the position of CMO. In this role, he led all development functions which included biometrics, regulatory, clinical science, clinical operations, drug safety, and pharmacology.
Franck Mevellec Appointed Senior Director, Business Development at Asymchem
Franck Mevellec boasts a proven track record of success, having held key positions at industry leaders like Bayer Healthcare (R&D), Teva Pharmaceuticals (portfolio director), Minakem (BD director), and most recently, Seqens (global head of sales). He joins Asymchem with a focus on expanding the company’s footprint across Europe.
Veristat Appoints Dr Gabriela Rosu to Lead Growing Medical Affairs Team
Dr Gabriela Rosu is a seasoned professional with over twenty years of experience in scientific and clinical fields, having significantly contributed to the planning and execution of pivotal activities that have led to the approval and commercialization of groundbreaking therapies.